Earnings continue to show losses. For 2025 on a standalone basis, the filing showed revenue of 885, operating income of -17,291, net income of -20,092, total assets of 170,610, total liabilities of 124,435 and total equity of 46,175, and earnings per share were also negative.
The figures appear to be in KRW millions, which means an operating loss of 17,291 and a net loss of 20,092. Total liabilities exceed total equity. For comparison, per FnGuide data, the 2024 operating loss was KRW 167 billion. Annual R&D spending rose from KRW 5.6 billion in 2022 and KRW 5.8 billion in 2023 to KRW 13.7 billion in 2024.
Clinical progress is visible. Topline PG-102 Phase 2a data in type 2 diabetes were presented at AIBIS, with 48 patients enrolled. Press coverage at the time reported a maximum HbA1c reduction of 1.44%.
At ADA 2026, glycemic improvement, fat-centered body composition improvement and gastrointestinal tolerability were reported, and no vomiting was reported in the monthly dosing group.
As a follow-up, the Ministry of Food and Drug Safety approved a high-dose Phase 1 trial, designed as 12-week repeated dosing in obese subjects to confirm the dose-response relationship.
There were also funding and governance developments. ProGen raised KRW 22 billion, made up of KRW 8 billion in convertible preferred shares and KRW 14 billion in convertible bonds.
It later issued KRW 2.8 billion in convertible bonds to its largest shareholder Yuhan and founder Young-Chul Sung, the former Genexine chairman. At the March 31, 2026 shareholder meeting, President Byung-Hwa Lee was newly elected as an inside director.
He bought 5,000 common shares on the market between May 6 and May 8, 2026. The share price has trended lower. The March 31, 2026 close was KRW 6,170, the intraday price on May 13, 2026 was KRW 4,695, and the price on October 8, 2026 was reported at KRW 2,300.
The October 27, 2026 close was KRW 2,055, with a market capitalization of KRW 31.6 billion and trading value of KRW 10,784,836.